Genocea Biosciences
GNCA
$0.0001000
Share price
-85.71%
Change (1 day)
N/A
Change (1 year)
Categories
Operating Margin for Genocea Biosciences (GNCA)
Operating Margin as of April 2024 (TTM): -1,084.89%
According to Genocea Biosciences 's latest financial reports and stock price the company's current Operating Margin is -1,084.89%. At the end of 2021 the company had an Operating Margin of -2,022.91%.
Operating Margin history for Genocea Biosciences from 2013 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -2,022.91% | -37.11% |
| 2020 | -3,216.63% | |
| 2016 | -21,094.89% | 232.69% |
| 2015 | -6,340.75% | -44.67% |
| 2014 | -11,459.74% | 302.63% |
| 2013 | -2,846.24% | 320.96% |
| 2012 | -676.13% | -16.2% |
| 2011 | -806.87% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | -103.19% | 🇺🇸 USA |
 Merck MRK | 27.73% | -102.56% | 🇺🇸 USA |
 Novavax NVAX | -149.57% | -86.21% | 🇺🇸 USA |
 Agenus
AGEN | -9.71% | -99.10% | 🇺🇸 USA |
 iBio IBIO | -2,110.95% | 94.58% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.